Long-term disease activity and disability progression in relapsing-remitting multiple sclerosis patients on natalizumab

• Published in: Multiple sclerosis and related disorders 2019-08, Vol.33, p.82-87
• Main Authors: Dekker, I., Leurs, C.E., Hagens, M.H.J., van Kempen, Z.L.E., Kleerekooper, I., Lissenberg-Witte, B.I., Barkhof, F., Uitdehaag, B.M.J., Balk, L.J., Wattjes, M.P., Killestein, J.
• Format: Article
• Language: English
• Subjects: Adult; Disability Evaluation; Disability progression; Disease activity; Disease modifying treatment; Disease Progression; Female; Humans; Immunologic Factors - therapeutic use; Male; Multiple sclerosis; Multiple Sclerosis, Relapsing-Remitting - drug therapy; Natalizumab; Natalizumab - therapeutic use
• ISSN: 2211-0348; 2211-0356
• DOI: 10.1016/j.msard.2019.05.017

•A long disease duration at natalizumab initiation predicts earlier EDSS progression.•A higher pre-baseline relapse rate predicts a longer NEPAD status.•Considering early effects of natalizumab, 43.7% of patients showed progression.•Long-term EDSS improvement was seen in 17.8% of the patients using natalizumab. Natalizumab is an effective treatment for relapsing-remitting multiple sclerosis (RRMS). Data on clinical and imaging measures predictive of disease activity and progression during treatment is limited. To determine clinical and imaging predictors of long-term inflammatory disease activity and disability progression in RRMS patients on natalizumab. Patients (n = 135) were selected from our prospective observational natalizumab cohort and monitored using brain MRI and extensive clinical testing. Progression and improvement on the Expanded Disability Status Scale (EDSS), no evidence of disease activity (NEDA) and no evidence of progression or active disease (NEPAD) status were determined using measurements after the initial phase of inflammation and the early anti-inflammatory impact of natalizumab. EDSS progression was seen in 43.7% of patients and EDSS improvement in 17.8%. Median follow-up was 4.9 years (IQR 3.6–6.0). Patients with a longer disease duration at natalizumab initiation have a higher hazard for earlier EDSS progression (HR 1.05, CI 1.00–1.09, p = 0.037) and a higher pre-baseline relapse rate predicted a longer NEPAD status (HR 1.70, CI 1.06–2.72, p = 0.028). The results suggest that starting natalizumab early, during active inflammatory disease results in a more favourable outcome. When taking into account early inflammation and the impact of natalizumab on disease activity during the initial treatment phase, a higher than expected proportion of patients showed disability progression.